CAS 163042-96-4|2-CL-IB-MECA
| Common Name | 2-CL-IB-MECA | ||
|---|---|---|---|
| CAS Number | 163042-96-4 | Molecular Weight | 544.731 |
| Density | 2.0±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C18H18ClIN6O4 | Melting Point | 209 °C |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide |
|---|---|
| Synonym | More Synonyms |
2-CL-IB-MECA BiologicalActivity
| Description | Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Adenosine ReceptorResearch Areas >>Cancer |
| Target | Ki:0.33 nM (A3 adenosine receptor)[1][2]. |
| In Vitro | In human ADF cells of astroglial lineage, 100 nM Namodenoson (2-Cl-IB-MECA) caused a marked reorganization of the cytoskeleton, with appearance of stress fibres and numerous cell protrusions. High concentrations of Namodenoson (2-Cl-IB-MECA) directly cause influx of Ca2+[2]. |
| In Vivo | Intravenous administration of 200 μg/kg Namodenoson (2-Cl-IB-MECA) resulted in a short-lasting hypotension, which was accompanied by a 50-100-fold increase in plasma histamine concentrations. Administration of a second dose of Namodenoson (2-Cl-IB-MECA) did not elicit any hemodynamic effects[1]. |
| References | [1]. Van Schaick EA et al. Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol. 1996 Jul 25;308(3):311-4. [2]. Jacobson KA et al. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998 May;19(5):184-91. |
Chemical & Physical Properties
| Density | 2.0±0.1 g/cm3 |
|---|---|
| Melting Point | 209 °C |
| Molecular Formula | C18H18ClIN6O4 |
| Molecular Weight | 544.731 |
| Exact Mass | 544.012268 |
| PSA | 134.42000 |
| LogP | 3.14 |
| Index of Refraction | 1.814 |
| InChIKey | IPSYPUKKXMNCNQ-PFHKOEEOSA-N |
| SMILES | CNC(=O)C1OC(n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)C(O)C1O |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2934999090 |
Customs
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles5
More Articles| The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma. Cancer Chemother. Pharmacol. 74(4) , 847-60, (2014) Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the deadliest form of skin cancer. Melanoma progression is associated with the abrogation of normal control... | |
| Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J. Neurosci. 17 , 607-614, (1997) The adenosine A3 receptor is expressed in brain, but the consequences of activation of this receptor on electrophysiological activity are unknown. We have characterized the actions of a selective aden... | |
| Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell Death Dis. 5 , e1539, (2014) Therapies that target the signal transduction and biological characteristics of cancer stem cells (CSCs) are innovative strategies that are used in combination with conventional chemotherapy and radio... |
Synonyms
| CF102 |
| CI-IB-MECA |
| 2-Cl-IB-Meca |
| Cl-IB-MECA |
| Namodenoson |
| 2-chloro-IB-MECA |
| (2S,3S,4R,5R)-5-{2-Chloro-6-[(3-iodobenzyl)amino]-9H-purin-9-yl}-3,4-dihydroxy-N-methyltetrahydro-2-furancarboxamide (non-preferred name) |
| UNII:Z07JR07J6C |
| CF-102 |
| CF-102(2-Cl-IB-MECA) |
